Furthermore, a prospective study of 3879 participants with stages 2–4 CKD found that elevated FGF-23 was an independent risk factor for end-stage kidney disease (ESKD) and progression to dialysis in patients with relatively preserved kidney function, and for mortality across all stages of CKD enrolled [51]. Here, FGF23 is linked to chronic kidney disease.